Becton, Dickinson and Company (BDX) - NYSE
  • Fri, Jan. 8, 10:57 AM
    • Germany-based Fresenius Kabi acquires Becton, Dickinson and Company's (BDX -0.2%) Rx business for an undisclosed sum. The deal includes a pharmaceutical manufacturing plant in Wilson, NC and the BD Simplist line of seven drugs in pre-filled glass syringes.
    • The companies also inked a 10-year supply and distribution agreement under which Fresenius will supply BD with a portfolio of intravenous solutions. Both firms intend to launch a range of IV solutions in the U.S. this year.
    | Fri, Jan. 8, 10:57 AM
  • May 28, 2015, 12:51 PM
    • Sources close to the matter report that Becton, Dickinson & Company (BDX -0.1%) has hired JP Morgan Chase to assist it in divesting its V. Mueller surgical instruments business following its takeover of CareFusion. The transaction, which could fetch as much as $500M, is a move by the company to shed non-core assets.
    | May 28, 2015, 12:51 PM
  • Dec. 4, 2014, 9:58 AM
    | Dec. 4, 2014, 9:58 AM | 5 Comments
  • Oct. 13, 2014, 9:40 AM
    • Becton, Dickinson and Company (BDX -0.2%) acquires privately-held Limerick, Ireland-based GenCell Biosystems for an undisclosed sum.
    • GenCell has developed an automated platform that addresses key biological analysis protocols for library preparation of Next Gen Sequencing to genotyping for agricultural applications.
    • BDX will disclose the impact of the transaction in its Q4 earnings call.
    | Oct. 13, 2014, 9:40 AM
  • Oct. 5, 2014, 4:56 PM
    • Becton Dickinson (NYSE:BDX) will acquire CareFusion (NYSE:CFN) for $12.2B in cash and stock in a merger of medical-products makers.
    • CareFusion shareholders will receive $49 in cash and 0.0777 BDX share for each CFN share, based on BDX’s Oct. 3 closing price.
    • BDX expects the deal will add “double-digit” EPS accretion in its first full year.
    • BDX has $9.1B in fully committed bridge funding from Goldman (NYSE:GS).
    • The price represents a 26% premium to CFN’s Oct. 3 closing price of $46.17.
    • BDX CEO Vincent Forlenza: “BD’s acquisition of CareFusion allows us to align our highly complementary technologies and products to address unmet needs in the growing $20 billion global medication management industry, which leverages BD’s world-wide infrastructure. It accelerates BD’s transition from a product-focused company to a customer-centric provider of innovative healthcare solutions with leading scale across the medication management value chain and expanded solutions for patient safety.”
    | Oct. 5, 2014, 4:56 PM | 5 Comments
  • Jan. 7, 2014, 12:02 PM
    • Becton, Dickinson (BDX +1.6%) acquires privately-held Alverix, which makes diagnostic instruments.
    • The two companies have worked together for the last five years designing and developing the BD Veritor System.
    • The deal will be "minimally dilutive" to BDX's FY14 results and "will not impact ... 2014 earnings guidance." (PR)
    | Jan. 7, 2014, 12:02 PM
  • Apr. 10, 2012, 8:24 AM

    Corning (GLW) will acquire a majority of Becton Dickinson's (BDX) Discovery Labware unit for $730M in cash. Corning says the deal will enhance its portfolio of life sciences products and add to its effort to meet its $10B revenue target in the next few years. GLW +0.7%, BDX +0.7% premarket.

    | Apr. 10, 2012, 8:24 AM | 1 Comment
Company Description
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States